Scienture Holdings Inc(SCNX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -45.23 | Insider Own | 22.08% | Shs Outstand | 1.6M | Perf Week | -11.11% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 93.92% | Insider Trans | - | Shs Float | 1.3M | Perf Month | -6.17% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -1.57 | Inst Own | 5.26% | Short Float | 9.17% | Perf Quarter | -73.85% |
| Income | -0.02B | P/S | 7.68 | EPS this Y | 93.42% | Inst Trans | 5.99% | Short Ratio | 0.61 | Perf Half Y | -70.27% |
| Sales | 0.00B | P/B | 0.08 | EPS next 5Y | - | ROA | -20.29% | Short Interest | 0.12M | Perf YTD | -76.16% |
| Book/sh | 39.03 | P/C | 0.61 | EPS past 3/5Y | 23.94% 11.34% | ROE | -24.07% | 52W High | -84.39% ($19.47) | Perf Year | -83.58% |
| Cash/sh | 4.99 | P/FCF | - | Sales past 3/5Y | -65.21% -52.1% | ROIC | -27.9% | 52W Low | 15.15% ($2.64) | Perf 3Y | -96.59% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 92.38% | Gross Margin | 82.75% | Volatility(W/M) | 6.53% 8.52% | Perf 5Y | -99.67% |
| Dividend TTM | - | EV/Sales | 11.52 | Sales Y/Y TTM | -73.18% | Oper. Margin | -2648.49% | ATR (14) | 0.34 | Perf 10Y | -99.67% |
| Dividend Ex-Date | - | Quick Ratio | 2.97 | EPS Q/Q | 78.08% | Profit Margin | -3145.84% | RSI (14) | 33.12 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.04 | Sales Q/Q | 3249.96% | SMA20 | -3.71% ($3.16) | Beta | 3.49 | Target Price | $6 |
| Payout | - | Debt/Eq | 0.17 | Earnings | 2026/8/14 | SMA50 | -41.91% ($5.23) | Rel Volume | 0.03 | Prev Close | $3.04 |
| Employees | 9 | LT Debt/Eq | 0.15 | EPS/Sales Surpr. | 22.22% - | SMA200 | -65.48% ($8.81) | Avg Volume(3M) | 0.19M | Price | $3.04 |
| IPO | 2009/1/26 | Option/Short | No/Yes | Trades | 103 | Volume | 6,507 | Change | - |
💊 ScienHoldings () is a small publicly listed company that has transformed into a specialty pharmaceutical company focused on commercializing 505(b)(2)-based specialty drugs, after divesting its legacy healthcare IT and wholesale businesses. Its flagship products include FDA-approved losartan oral suspension Arbli™ and the nasal spray formulation of naloxone, REZENOPY™, licensed from Kindeva/Summit, and the company is currently working to penetrate the cardiovascular and central nervous system markets.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded less than usual. That is 3% of its average volume.
SCNX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +93.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $768. Peers typically go for $266. Compared with its own 1-year average, it is 93% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.7%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #4 of 5 in the industry
Based on market cap of $5M.
HITI#1 High Tide Inc $226M PER - 
PETS#2 Petmed Express Inc $23M PER - 
POM#3 Pomdoctor Ltd $14M PER - SCNX#4 Scienture Holdings Inc $5M PER - 
RDGT#5 Ridgetech Inc $4M PER - 
FAQ
What kind of company is SCNX?
SCNX belongs to the Healthcare sector and operates in the Pharmaceutical Retailers industry.
What is the market cap of SCNX?
The market cap of SCNX is approximately $5M, ranking 5,595 within its sector.
What is the 52-week high and low for SCNX?
SCNX has recorded a 52-week high of $19.47 and a low of $2.64.
